Replies to post #132391 on Avid Bioservices Inc (CDMO)

[Fire Fox]

Aikifred-- You make fair points.

In reply, it would just point out PPHM's entire communications MO is overwhelmingly cautious and conservative. I don't think they would re-brand the Company and announce both preclinical immunotherapy combo studies AND a clinical immunotherapy combo study to start before year-end unless the "well advanced" preclinical work had already yielded some very encouraging data.

[volgoat]

years in pre-clinical....

[freethemice]

I don't think that is an entirely fair characterization of how the new immunotherapy agents will be used.
WIth all the excitement about anti-PD1/PDL1/CTLA4 mabs they still do not work on the majority of patients.
In addition, at ASCO there were several posters about trials combining these mabs with chemotherapy. Here are three:
1) A Phase 1 Study of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Plus Platinum-based Doublet Chemotherapy
in Chemotherapy-naïve Non-small Cell Lung Cancer (NSCLC) Patients.
2) A Phase 1 Study of BMS-936558 Plus Sunitinib or Pazopanib in Patients With Metastatic Renal Cell Carcinoma.
3) A Phase 1 Study of BMS-936558 in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin,
or Carboplatin/Paclitaxel in Patients With Treatment-Naïve, Stage IIIB/IV Non-Small Cell Lung Cancer.